English

PhotoCure ASA - Second Quarter Results 2005

Report this content
Highlights from PhotoCure ASA's second quarter report 2005:


  • Hexvix launch initiated in Sweden and NDA for Hexvix filed in the US.
  • Galderma's sales of Metvix increased by 118% to 6 233 units, compared to 2 855 units in the second quarter of 2004. Galderma launched Metvix in Spain and Portugal.
  • Nordic Metvix sales increased by 21% to 3 129 units, compared to 2 582 units in the same period of 2004.
  • Total revenues increased to NOK 24.2 million, from NOK 14.7 million in the same quarter of 2004. Other operating revenues were NOK 11.4 million, compared to NOK 1.2 million in the second quarter of 2004.
  • Net loss amounted to NOK -7.2 million, compared to NOK -15.2 million in the second quarter of 2004.
  • Liquid funds at 30 June 2005 amounted to NOK 100.1 million.


President and CEO of PhotoCure, Kjetil Hestdal comments: "The main focus is now to build knowledge of Hexvix, emphasising its medical and economical benefits. We also need to establish a solid market platform. Signing a licensing agreement is an important part of our strategy."


The full report and the presentation of the second quarter of 2005 are available on www.photocure.com (see: /Investors/Reports and Presentations).


The report is also available at the following link:


The presentation is available at the following link:


For further information, please contact:
 
President and CEO Kjetil Hestdal
Mobile: +47 913 19 535
Office: +47 22 06 22 10
 
CFO Christian Fekete
Mobile: +47 916 42 938
Office: +47 22 06 22 10
 
 
PhotoCure ASA is a Norwegian pharmaceutical company listed on Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technologies, targeting key dermatology and oncology markets.
 
PhotoCure has two products with sales and marketing approvals: Metvix®, for the treatment of skin cancer (basal cell carcinoma) and pre-cancerous skin lesions (actinic keratosis), and Hexvix®, for the detection of bladder cancer. Both products are based on the same photodynamic technology, combining the drug known as a photosensitiser with a light source that activates the photosensitiser. PhotoCure is currently testing both products for new indications and aims to develop a pipeline of follow-on products and technologies.

Subscribe